Topic: Kaletra
Today we highlight five safe healthcare stocks that can strengthen any retirement portfolio, healthy and ailing alike. While it is no secret that...
Abbott Laboratories (ABT) is all set to announce its fourth quarter and full year 2010 results on January 26, 2011 before the opening bell. The...
Abbott Laboratories' (ABT) next big thing may not be coming at all. The company has announced that it is withdrawing psoriasis drug briakinumab...
India's patent office has denied protection to Abbott Laboratories' (ABT) AIDS drug Kaletra allowing generic drugmakers to continue selling their...
Kaletra is a medication consisting of several antiviral medicines together which doctors use for the treatment of HIV/AIDS. There are several medications which may not be taken with protease inhibitors such as Kaletra as they may cause side effects which could ...
WASHINGTON (Reuters) - U.S. regulators are investigating potential risks from Abbott Laboratories Inc's HIV drug Kaletra, GlaxoSmithKline Plc's prostate drug Avodart and other medicines.The Food and Drug Administration said on Monday it was probing reports of liver toxicity with ...
Abbott announced today that the U.S. Food and Drug Administration (FDA) approved once-daily dosing of Kaletra (lopinavir/ritonavir) for adult patients with HIV who have previously taken antiretroviral therapy. Kaletra once-daily dosing is already indicated for adult patients new to antiretroviral ...
ABT) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir (ritonavir). Do not take Norvir with certain medicines, as these can cause serious or life-threatening ...
Brazil and Abbott Labs - two key players in the recent debate over the price of AIDS drugs in the developing world - have agreed on a price for Abbott's drug Kaletra.. For Abbott, the deal removes the threat of Brazil issuing what ...
NEW YORK (Reuters) - The U.S. Food and Drug Administration sent a warning letter to Abbott Laboratories, citing what it called serious violations in a promotional DVD about its HIV drug Kaletra that the agency said includes misleading information about the medicine ...
